Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Physician-based Decision Support

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03443713
Recruitment Status : Completed
First Posted : February 23, 2018
Last Update Posted : May 14, 2019
Sponsor:
Collaborator:
DexCom, Inc.
Information provided by (Responsible Party):
Jessica Castle, Oregon Health and Science University

Brief Summary:
The goal of this study is to assess the impact of physician-driven insulin setting changes in type 1 patients using multiple daily injection insulin therapy with exercise. This is a short outpatient study with multiple outpatient and home exercise sessions with an assigned type of exercise.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Mellitus MDI CGM Exercise Device: Dexcom G6 CGM Not Applicable

Detailed Description:
Subjects will be on study for 28 days. Sensor glucose, exercise, insulin and meal data will be collected during this time. Subjects will wear the Dexcom G6 CGM system and a physical activity monitor. The Subjects will complete 2 exercise visits in-clinic and 4 exercise visits as an outpatient. Subjects will be randomized to aerobic, anaerobic or high intensity interval exercise sessions for 30 minutes each. Physicians will review CGM and insulin data every 7 days and make insulin dose recommendations that the subject will adjust in the dose calculator.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects randomly assigned to one of three types of exercise.
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Evaluation of Physician-based Decision Support in Patients With Type 1 Diabetes on Multiple Daily Injection Therapy
Actual Study Start Date : July 18, 2018
Actual Primary Completion Date : May 8, 2019
Actual Study Completion Date : May 8, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Aerobic exercise
Subjects in this arm will complete aerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
Device: Dexcom G6 CGM
Subjects will wear a Dexcom G6 CGM for the 28 days they are on study.

Experimental: Anaerobic exercise
Subjects in this arm will complete anaerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
Device: Dexcom G6 CGM
Subjects will wear a Dexcom G6 CGM for the 28 days they are on study.

Experimental: High intensity interval exercise
Subjects in this arm will complete high intensity interval exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
Device: Dexcom G6 CGM
Subjects will wear a Dexcom G6 CGM for the 28 days they are on study.




Primary Outcome Measures :
  1. Percent of time with sensed glucose 70-180 mg/dl [ Time Frame: Days 1-7 vs. Days 22-28 ]
    Assess the percent of time that the Dexcom G6 reported sensor glucose values between 70-180 mg/dl using values uploaded to Dexcom Clarity.

  2. Percent of time with sensed glucose less than 70 mg/dl [ Time Frame: Days 1-7 vs. Days 22-28 ]
    Assess the percent of time that the Dexcom G6 reported sensor glucose values less than 70 mg/dl using values uploaded to Dexcom Clarity.


Secondary Outcome Measures :
  1. Percent of time with sensed glucose less than 54 mg/dl [ Time Frame: Days 1-7 vs. Days 22-28 ]
    Assess the percent of time that the Dexcom G6 reported sensor glucose values less than 54 mg/dl using values uploaded to Dexcom Clarity.

  2. Mean sensed glucose [ Time Frame: Days 1-7 vs. Days 22-28 ]
    Assess the mean Dexcom G6 reported sensor glucose values using values uploaded to Dexcom Clarity.

  3. Mean absolute difference of the Dexcom G6 sensor [ Time Frame: 28 days of study ]
    Mean absolute difference of the Dexcom G6 sensor when reference capillary blood glucose is less than or equal to 75 mg/dl.

  4. Mean absolute relative difference of the Dexcom G6 sensor [ Time Frame: 28 days of study ]
    Mean absolute relative difference of the Dexcom G6 sensor when reference capillary blood glucose is greater than 75 mg/dl.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of type 1 diabetes mellitus for at least 1 year.
  • Male or female subjects 18 to 50 years of age.
  • Physically willing and able to perform 30 min of exercise (as determined by the investigator after reviewing the subject's activity level).
  • Use of multiple daily insulin injections (MDI).
  • A1C ≥7.0% at the time of screening.
  • Current use of a smart phone.
  • Willingness to follow all study procedures, including attending all clinic visits.
  • Willingness to sign informed consent and HIPAA documents.

Exclusion Criteria:

  • Female of childbearing potential who is pregnant or intending to become pregnant or breast-feeding, or is not using adequate contraceptive methods. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence.
  • Any cardiovascular disease, defined as a clinically significant EKG abnormality at the time of screening or any history of: stroke, heart failure, myocardial infarction, angina pectoris, or coronary arterial bypass graft or angioplasty. Diagnosis of 2nd or 3rd degree heart block or any non-physiological arrhythmia judged by the investigator to be exclusionary.
  • Renal insufficiency (GFR < 60 ml/min, using the MDRD equation as reported by the OHSU laboratory).
  • Liver failure, cirrhosis, or any other liver disease that compromises liver function as determined by the investigator.
  • Hematocrit of less than 36% for men, less than 32% for women.
  • History of severe hypoglycemia during the past 12 months prior to screening visit or hypoglycemia unawareness as judged by the investigator. Subjects will complete a hypoglycemia awareness questionnaire. Subjects will be excluded for four or more R responses.
  • Adrenal insufficiency.
  • Any active infection.
  • Known or suspected abuse of alcohol, narcotics, or illicit drugs.
  • Seizure disorder.
  • Active foot ulceration.
  • Peripheral arterial disease.
  • Major surgical operation within 30 days prior to screening.
  • Use of an investigational drug within 30 days prior to screening.
  • Chronic usage of any immunosuppressive medication (such as cyclosporine, azathioprine, sirolimus, or tacrolimus).
  • Bleeding disorder or platelet count below 50,000.
  • Allergy to aspart or glargine insulin.
  • Need for uninterrupted treatment of acetaminophen.
  • Current administration of oral or parenteral corticosteroids.
  • Any life threatening disease, including malignant neoplasms and medical history of malignant neoplasms within the past 5 years prior to screening (except basal and squamous cell skin cancer).
  • Beta blockers or non-dihydropyridine calcium channel blockers.
  • Current use of any medication intended to lower glucose other than insulin (ex. use of liraglutide).
  • A positive response to any of the questions from the Physical Activity Readiness Questionnaire with one exception: subject will not be excluded if he/she takes a single blood pressure medication that doesn't impact heart rate and blood pressure is controlled on the medication (blood pressure is less than 140/90 mmHg).
  • Any chest discomfort with physical activity, including pain or pressure, or other types of discomfort.
  • Any clinically significant disease or disorder which in the opinion of the Investigator may jeopardize the subject's safety or compliance with the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03443713


Locations
Layout table for location information
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239
Sponsors and Collaborators
Oregon Health and Science University
DexCom, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Jessica Castle, MD Oregon Health and Science University
Principal Investigator: Peter Jacobs, PhD Oregon Health and Science University

Layout table for additonal information
Responsible Party: Jessica Castle, Associate Professor, Oregon Health and Science University
ClinicalTrials.gov Identifier: NCT03443713     History of Changes
Other Study ID Numbers: 18023
First Posted: February 23, 2018    Key Record Dates
Last Update Posted: May 14, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases